Adaptive Trials, Platform Trials, Master Protocols and Beyond: Pathways to Transformation - or Not?
Access Video Here
Master protocols and adaptive platform trials are being heralded as potential pathways to more efficient, less expensive clinical trials that can move effective drugs and biologics to patients more quickly. Are these innovative approaches potentially effective solutions to the range of issues that plague the field of drug/biologics development? What are the pros and cons for the various stakeholders of creating and participating in these multi-sector partnerships? What lessons have been learned by those who have launched existing trials using these models? What outcomes have they achieved thus far – and what might the future hold?
Brian Alexander, Disease Center Lead, Center for Neuro-Oncology, Dana-Farber Cancer Institute
Jeff Allen, President and CEO, Friends of Cancer Research
Donald Berry, Professor, Department of Biostatistics, The University of Texas MD Anderson Cancer Center
Lisa LaVange, Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
Ronit Simantov, Vice President, Global Medical Affairs, Pfizer Oncology
Anna Barker, Professor and Director, Transformative Healthcare Networks; Co-Director, Complex Adaptive Systems Network, Arizona State University; Senior Fellow, FasterCures